News und Analysen
The Not-So-Subtle Reason Behind Perrigo Company PLC's 13% Move Higher
Shares of Perrigo (NYSE: PRGO), a provider of consumer goods and over-the-counter pharmaceutical products, rocketed higher by as much as 13% during Thursday's trading session after the company....
Why Inovio Pharmaceuticals Inc. Is Sinking Today
In response to the company reporting disappointing third-quarter results, shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage biotech focused on vaccines, fell 14% as of 2:15 p.m. EST....
Why Idera Pharmaceuticals Inc. Jumped Higher Today
Idera Pharmaceuticals (NASDAQ: IDRA) is up 14% at 11:46 a.m. EST after releasing data from a phase 1/2 trial testing its drug candidate IMO-2125 in combination with Bristol-Myers Squibb's (NYSE:....
2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
Shares of SAGE Therapeutics Inc. (NASDAQ: SAGE) are rocketing higher today in response to positive clinical trial data for a postpartum depression candidate. Investors are pushing up Marinus....
Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?
This week, Valeant Pharmaceuticals (NYSE: VRX) reported its earnings, and the market rewarded it with a 17% stock price bump. While the company's shares are still down 95% from their 2016 highs,....
Here's Why the Best Is Yet to Come for Novavax, Inc.
Synthetic vaccine maker Novavax (NASDAQ: NVAX) has fallen on hard times. The dramatic failure of its closely watched respiratory syncytial virus fusion (RSV F) vaccine in elderly adults last year....
Humana (HUM) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Humana (NYSE: HUM) Q3 2017 Earnings Conference CallNov. 8, 2017 9:00 pam. ETOperatorContinue readingSource: Fool.com
What You Need to Know From Inovio Pharmaceuticals' Q3 Update
Inovio Pharmaceuticals (NASDAQ: INO) continues to take investors on a roller coaster ride. The biotech stock was up close to 25% by late May, only to give up all of those gains and then some. A....
Editas Medicine Keeps Moving Forward
Editas Medicine (NASDAQ: EDIT) announced third-quarter 2017 results on Wednesday after the market closed, and shares of the CRISPR gene-editing specialist were down modestly on Thursday in....
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
This Gene Therapy Can Restore Vision, but Will It Break the Bank?
In October, Spark Therapeutics (NASDAQ: ONCE) took another step closer to FDA approval for its vision-restoring drug, Luxturna. An approval for the gene-editing therapy early next year would be a....
Why Five Prime Therapeutics Stock Is on the Rebound Today
After a whopping 41% drop yesterday, shares of the clinical-stage biotech Five Prime Therapeutics (NASDAQ: FPRX) are on the mend today as the result of an upbeat clinical update. Specifically,....
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Shares of Pacira Pharmaceuticals (NASDAQ: PCRX), which focuses on developing medicines to be used in the ambulatory or surgical setting, surged by as much as 24% during Wednesday's trading session....
Why Nektar Therapeutics Shares Are Soaring 13% Higher
After the company reported third-quarter earnings that were better than industry watchers' forecasts, shares in Nektar Therapeutics (NASDAQ: NKTR) are popping 13.1% higher today as of 2:45 p.m.....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
BASTIDE : Communiqué de mise à disposition des documents preparatoires AG du 30 novembre 2017
Société anonyme au capital de 3.303.261 euros
Siège social :
12, avenue de la Dame - Zone euro 2000
30132 CAISSARGUES
305 635 039 RCS NÎMES
ASSEMBLEE GENERALE DU 30 NOVEMBRE 2017
MODALITES DE....
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more....
BASTIDE : Nombre d'actions et de droits de vote au jour de l'avis de réunion (25.10.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Droits de vote....
How to Invest in Biotech Stocks
$33,800.That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago.Sound enticing? How about $154,980?Continue readingSource: Fool.com
Here's Why Editas Medicine Collapsed at Market Open Today
Shares of CRISPR gene-editing pioneer Editas Medicine (NASDAQ: EDIT) fell 12.1% shortly after the market opened Wednesday morning. Why? Although the company reported third-quarter 2017 earnings....
Mazor Robotics Enters a New Era
Mazor Robotics (NASDAQ: MZOR), a robotic surgery company focused on spine and brain procedures, reported its third-quarter results on Tuesday, Nov 7th. Revenue more than doubled, margins expanded,....
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took....